Methodology of a new inflammatory arthritis registry: TReasure

doi:10.3906/sag-1807-200

Cited by 6 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TReasure registry is a web-based, prospective, observational cohort including RA and spondyloarthritis (SpA) patients from 17 centers in different regions of Turkey and was established in December 2017. Details of the establishment of TReasure registry were previously reported [7]. As of March 2020, there were a total of 7471 patients with inflammatory arthritis (2560 RA patients and 4911 SpA patients) receiving bDMARDs in this registry.…”

Section: Patient Selectionmentioning

confidence: 99%

“…The demographic and clinical data collected from the patients were defined previously [7]. In brief, the following data were recorded for both RA and SpA patients: age, sex, disease duration, comorbidities (the Charlson comorbidity index), erythrocyte sedimentation rate (ESR) (mm/h), C-reactive protein (CRP) level (mg/L), number of swollen (66 joints) and tender (68 joints) joints, visual analog scale (VAS)-pain score, patients' global assessment-VAS, and VAS-fatigue score, and the names of the currently used synthetic DMARDs or bDMARDs.…”

Section: Demographic and Clinical Characteristics Of The Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Kalyoncu¹,

Pehlıvan²,

Akar³

et al. 2021

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6–9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients’ data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21–73] vs. 44 years [20–79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.

show abstract

Section: Patient Selectionmentioning

confidence: 99%

Section: Demographic and Clinical Characteristics Of The Patientsmentioning

confidence: 99%

Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Kalyoncu¹,

Pehlıvan²,

Akar³

et al. 2021

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…Data of the study were retrieved from the TReasure registry, in which data of RA and SpA patients starting on bDMARD therapy were recorded. 4 These patients were evaluated in three groups: (1) post-pandemic group consisted of patients starting on bDMARD therapy for the first time within the first 6 months (Post-p A) and (2) within the second 6 months (Post-p B) after March 11, 2020, when the first case of COVID-19 was confirmed in Turkey and (3) the pre-pandemic group consisted of patients starting on bDMARD therapy for the first time within 6 months (Pre-p) before March 11, 2020. Although tofacitinib is not a bDMARD, patients using this medicine were also included in the study as tofacitinib is a second-line treatment option for RA like bDMARDs, and it has a similar risk profile with bDMARDs.…”

Section: Methodsmentioning

confidence: 99%

The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database

Kanıtez¹,

Kiraz²,

Dalkılıç³

et al. 2023

Eur J Rheumatol

View full text Add to dashboard Cite

Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic.

show abstract

“…Patients and Design: TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identi er and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data of in ammatory rheumatic diseases such as RA and SpA [29]. Patients older than 18 years of age, with a diagnosis of RA or SpA, ful lling 2010 American College of Rheumatology (ACR)/EULAR [30] and Assessment of Spondyloarthritis International Society (ASAS) criteria [31] were initially screened.…”

Section: Methodsmentioning

confidence: 99%

Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?

et al. 2022

View full text Add to dashboard Cite

Background: Several societies published recommendations for latent tuberculosis infection (LTBI) screening before biological and targeted synthetic diseasemodifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) but not for other in ammatory arthritides such as spondyloarthritis (SpA). Using RA guidelines could result in overestimating Tuberculin Skin Test (TST) positivity in SpA. This study aimed to compare the distribution of TST results in SpA and RA patients along with comparison in terms of QuantiFERON®-TB Gold In-Tube (QFT-GIT) test in a Bacillus Calmette-Guérin-vaccinated population.Methods: Adult RA (n=206) and SpA (n=392) patients from the TReasure database who had both TST and QFT-GIT prior to initiation of biological and targeted synthetic DMARDs were included in the study. Demographic and disease characteristics along with pre-biologic DMARD and steroid use were recorded. The distribution of TST and performance with respect to QFT-GIT were compared between RA and SpA groups.Results: Pre-biologic conventional DMARD and steroid use was higher in the RA group. TST positivity rates were 44.2% in RA and 69.1% in SpA for a 5 mm cutoff (p<0.001). QFT-GIT positivity was slighlty higher in the SpA group (15% vs 8.9%, p=0.075). QFT-GIT positivity and disease category independently predicted a 5 mm or higher TST. The two tests poorly agreed in both groups at a TST cut-off of 5 mm (κ<0.1 for both groups). Increasing the TST cut-off only slightly increased the agreement between the two tests.Conclusions: TST positivity was more pronounced in SpA compared to that in RA and this was not explainable by pre-biologic DMARD and steroid use. The agreement of TST with QFT-GIT was poor in both groups. Using a 5 mm TST cut-off for both diseases could result in overestimating LTBI in SpA.

show abstract

Methodology of a new inflammatory arthritis registry: TReasure

Cited by 6 publications

References 22 publications

Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database

Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?

Contact Info

Product

Resources

About